Navigation Links
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Date:8/19/2007

kidney injury caused by ischemia-reperfusion. Our drug could potentially offer a lifesaving treatment for this severe disease, which exhibits high rates of morbidity and mortality and represents a very serious unmet medical need. We have an open IND for AKIi-5 and expect to initiate a Phase I trial for the prevention of ARF through the systemic delivery of AKIi- 5 in patients undergoing major cardiac surgery. Based on publicly available information, we believe that this will be the first human clinical trial involving the systemic delivery of siRNA."

About AKIi-5

AKIi-5 is a synthetic, chemically modified siRNA molecule designed to temporarily inhibit the expression of p53, a gene which plays a significant role in ARF by inducing tubular cell death (apoptosis) in response to injury. AKIi-5 is based on Quark's proprietary, patented concept of temporary and reversible inhibition, for therapeutic purposes, of the expression of the transcription factor human p53, which is associated with DNA repair and apoptosis. Using RNA interference technology to temporarily inhibit p53 in acute settings such as acute kidney injury, apoptosis is delayed thereby allowing natural repair mechanisms to restore normal DNA and cellular integrity. The AKIi-5 molecule was designed and patented by Quark. The Company has licenses for AtuRNAi(TM) technology from Silence Therapeutics and additional RNAi intellectual property from Alnylam.

About Acute Renal Failure (ARF)

ARF is a syndrome characterized by a rapid decline of kidney function leading to death in a high percentage of cases. Major cardiac surgery is one of the many causes of ARF. During cardiac bypass surgery, lack of oxygen caused by reduced local blood flow to the kidneys, followed by rapid reintroduction of oxygen, or reperfusion, to the kidneys upon removal of the patient from cardiopulmonary bypass, initiates a chain of events that can lead to ARF. Currently, there are no approved drug therapies that effec
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ...  report to their offering. Global Guidewires sector is ... North America accounts for nearly 35% ... claims approximately 25% (2018). Asia-Pacific ...
(Date:12/15/2014)... , Dec. 15, 2014  Inovio Pharmaceuticals, ... it has been added to the NASDAQ Biotechnology ... Index will become effective upon market open on ... Index is designed to track the performance of ... as either biotechnology or pharmaceutical according to the ...
Breaking Medicine Technology:MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... 2011 American Scientific Resources, Inc. ("American Scientific ... Martin E. Janis & Company, Inc., the 61-year ... out a fully-integrated marketing and communications program for ... http://photos.prnewswire.com/prnh/20110124/NY34439LOGO) The firm will be responsible ...
... Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - ... and develops new uses for previously approved drugs and ... first patient in the three-arm, placebo controlled, 60 patient ... active ingredient in Ampion ™ has extensive worldwide ...
Cached Medicine Technology:American Scientific Resources Retains National PR/IR Firm 2American Scientific Resources Retains National PR/IR Firm 3Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia 2Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia 3
(Date:12/17/2014)... NY (PRWEB) December 17, 2014 Project ... who recently brought videos of MIT economist and Obamacare ... best-selling author James O’Keefe conducted the interview, which is ... stated that there was intentional mislabeling in the Affordable ... in the bill: A two-hundred-and-fifty billion dollar per year ...
(Date:12/17/2014)... News) -- Poor students get more fruits and vegetables at ... But, the opposite is true for students from wealthier ... at school may give a healthy boost to poor students, ... the family income level, students all ate a similar amount ... The study was published recently in the journal Preventive ...
(Date:12/17/2014)... By Kathleen Doheny ... -- Chronic sleep loss is rampant in America, and work ... "Work is the No. 1 sleep killer," said Dr. Mathias ... at the University of Pennsylvania Perelman School of Medicine. ... and older, found that work is the main activity exchanged ...
(Date:12/15/2014)... Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s first full-time ... providing evidence on the impact of 100% pure fruit ... enough evidence already exists showing a negative link between ... the onset of tooth decay. One question that has ... fruit juice, meaning it is completely natural with no ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Health ... solutions, announced today that it has received Patient ... Assurance (NCQA) for its Disease Management (DM) Programs ... disease (COPD), coronary heart disease and diabetes. This ... NCQA for Health Dialog’s Disease Management (DM) Programs, ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2
... that control coordinate gene expression is a long-standing ... sequences from multiple vertebrate or invertebrate // species ... to the dynamic interplay between a gene and ... footprinting, is based on the hypothesis that functionally ...
... aspects of human behaviour; they impact upon the foods we ... avoid and the people with whom we spend time // ... has been proposed that the brain uses it as a ... behaviors. Stimulus evaluation is also thought to be immediate, unintentional ...
... researchers have found that 70 percent of the children ... than those who drank adequately fluoridated water. , ... // more than 250,000 children. Jason Armfield, a researcher ... the University of Adelaide was categorical in saying that ...
... It is important for fish food to be cooked the right ... the cooking preparation is as important as the amount of fat ... into the nutrition facts? Just one piece of batter-dipped fish has ... accompanied by fried stuff, hushpuppies and coleslaw will probably give you ...
... that therapeutics based on monoclonal antibodies (mAbs) are fare ... molecule predecessors. According to a study completed by // ... fare appear to be profitable. That means mAbs are ... to $1.8 billion cost of development and marketing. By ...
... Smoking ban around the world can be materialized by increasing ... enforcing current regulations that prevent or delay youth smoking according ... to improve the lives of billions of people addicted to ... suggestion and act accordingly., , “Our research shows that ...
Cached Medicine News:Health News:Evoprinter, a multigenomic comparative tool for rapid identification of functionally important DNA 2Health News:Conditioning preferences in children 2Health News:Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs 2Health News:Lawmakers alerted on new tobacco control policies by research team 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: